Day One Biopharmaceuticals, Inc. ( (DAWN) ) has released its Q4 earnings. Here is a breakdown of the information Day One Biopharmaceuticals, Inc. presented to its investors.
Day One Biopharmaceuticals, Inc., based in Brisbane, California, is a biopharmaceutical company focused on developing and commercializing targeted therapies for life-threatening diseases, particularly pediatric cancers. The company recently reported its financial results for the fourth quarter and full year of 2024, highlighting significant achievements and progress in its corporate strategy.
In 2024, Day One Biopharmaceuticals achieved net product revenues of $57.2 million from its flagship drug, OJEMDA, which was launched in April 2024. The drug, designed for relapsed or refractory pediatric low-grade glioma, saw a 44% increase in net product revenues from the third to the fourth quarter. The company ended the year with a strong cash position of $531.7 million, reflecting its robust financial health.
Key financial metrics from the report include a net loss of $95.5 million for the year, an improvement from the previous year’s loss of $188.9 million. The increase in research and development expenses, totaling $227.7 million, was attributed to significant investments in advancing their pipeline, including the DAY301 program. Selling, general, and administrative expenses also rose to $115.5 million, driven by costs associated with the launch of OJEMDA.
Looking ahead, Day One Biopharmaceuticals remains optimistic about its growth trajectory, supported by the successful launch of OJEMDA and ongoing clinical trials. The company is advancing its global Phase 3 FIREFLY-2 clinical trial and expects full enrollment by the first half of 2026, positioning itself for continued innovation and expansion in the biopharmaceutical sector.